Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. touchRESPIRATORY were delighted to speak with Dr. Barbara Yawn (University of Minnesota, Minneapolis, MN, USA) to discuss whether people with asthma or COPD should be vaccinated against HZ and the impact these respiratory disorders have on incidence rates and risk of complications from HZ infection.
The abstract ‘RISK FACTORS FOR HERPES ZOSTER VIRUS: SHOULD PEOPLE WITH ASTHMA OR COPD BE VACCINATED?.’ (Poster 2030) was presented at CHEST 2022, 16-19 October, 2022 based on a study funded by GSK Biologics SA.
- Should herpes zoster (HZ) vaccination be added to the care of people with asthma or chronic obstructive pulmonary disease (COPD)? (0:17)
- What are the incidence and symptoms of HZ infection? (0:43)
- What impact does asthma or COPD diagnosis have on incidence rates and risk of complications from HZ infection? (2:29)
Disclosures: Barbara Yawn discloses consulting for and serving on advisory boards for GSK, AZ, BI and TEVA.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the CHEST meeting 2022.
Share this Video
Related Videos In COPD
Air pollution and respiratory diseases: Claudia Traidl-Hoffmann, EAACI 2023
Air pollution has been linked to exacerbating and causing symptoms associated with respiratory diseases, particularly impacting patients with asthma, COPD and allergic disease. touchRESPIRATORY were delighted to speak with Prof. Claudia Traidl-Hoffmann (University in Augsburg, Germany) around the symptoms associated with exposure to air pollution, the impact of air pollution on existing respiratory conditions and […]
BOREAS: phase 3 study of dupilumab in COPD: Klaus F. Rabe, ATS 2023
The phase 3 BOREAS study (NCT03930732) investigated the efficacy and safety of dupilumab for the treatment of chronic obstructive pulmonary disease with type 2 inflammation. It was a pleasure to talk with Prof. Klaus F. Rabe (University of Kiel, Germany) around the aims, design, inclusion criteria and findings from the phase 3 study and the […]
Dupilumab: an investigational monoclonal antibody for COPD: Klaus F. Rabe, ATS 2023
Dupilumab is an investigational monoclonal antibody that mitigates type 2 inflammation by blocking IL-4 and IL-13 receptors in patients with COPD. We were delighted to talk with Prof. Klaus F. Rabe (University of Kiel, Germany) around the unmet needs in the treatment of COPD, the association between type 2 inflammation and COPD exacerbations and the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!